Articles From: Amazon investors roll the dice on earnings to Obamacare gives a lift to insurer Molina's results


2015/1/29
By Russ Britt, MarketWatch Seven of last 10 reports have fallen short of Wall Street views LOS ANGELES (MarketWatch) -- Amazon.com Inc. investors are bracing themselves for what has become a quarterly roll of the dice, as they wonder whether the online retailer will disappoint them yet again when it reports earnings after the market close on Thursday.
Sign-up for Amazon investors roll the dice on earnings investment picks
2015/1/30
By Russ Britt, MarketWatch Earnings, FDA ruling come into play for biopharmas LOS ANGELES (MarketWatch)--Two drug maker stocks posted double-digit gains on Friday as Biogen Idec Inc. surged on a strong earnings report and Intercept Pharmaceuticals Inc. won a critical ruling from the U.S. Food and Drug Administration.
Sign-up for Biogen, Intercept post double-digit gains investment picks
2015/2/2
By Russ Britt, MarketWatch Company says drug proved 100% effective in lab mice tests LOS ANGELES (MarketWatch) -- A tiny biotechnology company said Monday that it just may have an effective treatment for the deadly Ebola virus.
Sign-up for Tiny biotech says it may have an answer for Ebola investment picks
2015/2/2
By Russ Britt, MarketWatch Boosted internal forecasts, high outside praise play a role LOS ANGELES (MarketWatch) -- When HCA Holdings Inc. reports earnings early Tuesday, one thing to watch for in addition to fourth-quarter results will be whether the nation's biggest hospital chain can live up to its own raised expectations and the praise it received from outsiders last month.
Sign-up for What to look for in HCA earnings investment picks
2015/2/2
By Russ Britt, MarketWatch $1,000-a-day hepatitis C drugs figure prominently in results It's probably a foregone conclusion that anyone who has even heard of Gilead Sciences Inc. will be watching to see how the biotechnology company's sales of its hit hepatitis C drugs did when it reports fourth-quarter earnings after the close Tuesday.
Sign-up for What to look for in Gilead earnings investment picks
2015/2/4
By Russ Britt, MarketWatch Shares drop as investors fear high margins will come to an end LOS ANGELES (MarketWatch)--The future appeared golden when Gilead Sciences Inc. reported its results Tuesday, with earnings per share blowing past forecasts and revenue beating estimates by more than half a billion dollars.
Sign-up for Gilead to discount its pricey Sovaldi drug investment picks
2015/2/3
By Russ Britt, MarketWatch $1,000-a-day hepatitis C drugs figure prominently in results It's probably a foregone conclusion that anyone who has even heard of Gilead Sciences Inc. will be watching to see how the biotechnology company's sales of its hit hepatitis C drugs did when it reports fourth-quarter earnings after the close Tuesday.
Sign-up for UPDATE: What to look for in Gilead earnings investment picks
2015/2/4
By Russ Britt, MarketWatch Shares drop as investors fear high margins will come to an end LOS ANGELES (MarketWatch)--The future appeared golden when Gilead Sciences Inc. reported its results Tuesday, with earnings per share blowing past forecasts and revenue beating estimates by more than half a billion dollars.
Sign-up for UPDATE: Gilead to discount its pricey Sovaldi drug investment picks
2015/2/3
By Russ Britt, MarketWatch Measles outbreak not expected to slow entertainment giant A measles outbreak at its California resort notwithstanding, the earnings juggernaut that is Walt Disney Co.
Sign-up for UPDATE: What to look for in Disney earnings investment picks
2015/1/27
By Russ Britt, MarketWatch Drug giant overcomes patent woes and beats forecasts LOS ANGELES (MarketWatch) -- While the rest of the market was sinking, shares of drug giant Pfizer Inc. managed to eke out gains early Tuesday after Wall Street decided the company's fourth-quarter results were more critical than its 2015 projections.
Sign-up for Pfizer ekes out gains on a down market day investment picks
2015/2/24
By Russ Britt, MarketWatch Street watches for seventh straight upside surprise from company LOS ANGELES (MarketWatch) -- Investors will be watching to see if Cablevision Systems Corp.
Sign-up for What to look for in Cablevision earnings investment picks
2015/2/23
By Russ Britt, MarketWatch Market sees starting point in negotiations as positive for sector When is a loss a gain?
Sign-up for Proposed Medicare loss is a gain for insurers investment picks
2015/2/23
By Russ Britt, MarketWatch Deal is just above Friday closing price; Salix shares stumble LOS ANGELES (MarketWatch) -- Shares of Valeant Pharmaceuticals International Inc. soared by more than 14% at one point in morning trades Monday after the drug company said it was buying Salix Pharmaceuticals Ltd.
Sign-up for Valeant soars on plan to buy Salix for $10 billion investment picks
2015/2/23
By Russ Britt, MarketWatch Moore, Redmayne are top actors; 'Budapest' wins four awards LOS ANGELES (MarketWatch) -- "Birdman," the quirky tale of a Hollywood action hero's attempt to make a comeback via the Broadway stage, was declared the best picture of 2014 at Sunday's Academy Awards, taking four prizes in all and eking out a victory over "Boyhood." Eddie Redmayne, the British actor who took on the role of ALS-afflicted physicist Stephen Hawking, won the best-actor Oscar for "The Theory of Everything." Industry veteran Julianne Moore, a five-time nominee, won her first Oscar for playing a patient struck with early-onset Alzheimer's disease in the film "Still Alice." "Birdman" director Alejandro Inarritu won the Oscar for best director, as well as best screenplay and best cinematography.
Sign-up for UPDATE: 'Birdman' wins four Oscars, including best picture investment picks
2015/2/23
By Russ Britt, MarketWatch Moore, Redmayne are top actors; 'Budapest' wins four awards LOS ANGELES (MarketWatch) -- "Birdman," the quirky tale of a Hollywood action hero's attempt to make a comeback via the Broadway stage, was declared the best picture of 2014 at Sunday's Academy Awards, taking four prizes in all and eking out a victory over "Boyhood." Eddie Redmayne, the British actor who took on the role of ALS-afflicted physicist Stephen Hawking, won the best-actor Oscar for "The Theory of Everything." Industry veteran Julianne Moore, a five-time nominee, won her first Oscar for playing a patient struck with early-onset Alzheimer's disease in the film "Still Alice." "Birdman" director Alejandro Inarritu won the Oscar for best director, as well as best screenplay and best cinematography.
Sign-up for 'Birdman' wins four Oscars, including best picture investment picks
2015/2/20
By Russ Britt, MarketWatch Favorites 'Birdman,' 'Boyhood' losing steam ahead of Oscars 2015 Winners will no doubt be raising their glasses after the last award is handed out at Sunday's Oscar ceremonies, but there are few expectations this year's best picture will experience anything worth toasting at the box office in coming weeks.
Sign-up for UPDATE: Academy Awards winners may not reap box-office rewards investment picks
2015/2/20
By Russ Britt, MarketWatch Favorites 'Birdman,' 'Boyhood' losing steam ahead of awards Winners will no doubt be raising their glasses after the last award is handed out at Sunday's Oscar ceremonies, but there are few expectations this year's best picture will experience anything worth toasting at the box office in coming weeks.
Sign-up for UPDATE: Box-office rewards may bypass Oscar winners investment picks
2015/2/19
By Russ Britt, MarketWatch Favorites 'Birdman,' 'Boyhood' losing steam ahead of awards Winners will no doubt be raising their glasses after the last award is handed out at Sunday's Oscar ceremonies, but there are few expectations this year's best picture will experience anything worth toasting at the box office in coming weeks.
Sign-up for Box-office rewards may bypass Oscar winners investment picks
2015/2/18
By Russ Britt, MarketWatch J&J lawsuit was 'major overhang' on stock, analysts say For much of the past decade, Boston Scientific Corp.
Sign-up for Time for Boston Scientific shares to break out? investment picks
2015/2/18
By Russ Britt, MarketWatch Retailer warns of $150 billion annual burden on health care Drug retail giant CVS Health Corp.
Sign-up for UPDATE: CVS girds for battle over cholesterol drugs investment picks
2015/2/17
By Russ Britt, MarketWatch Drug retail giant CVS Health Corp.
Sign-up for CVS Girds For Battle Over Cholesterol Drugs investment picks
2015/2/17
By Russ Britt, MarketWatch Retailer warns of $150 billion annual burden on health care Drug retail giant CVS Health Corp.
Sign-up for CVS girds for battle over cholesterol drugs investment picks
2015/2/13
By Russ Britt, MarketWatch Prana tumbles again after FDA puts hold on drug trial LOS ANGELES (MarketWatch)--Shares of drug maker GlaxoSmithKline jumped more than 4% Friday after brokerage UBS turned 180 degrees and upgraded the British multinational to "buy" from "sell." Shares of Glaxo (GSK) climbed $1.93 to $47.88 in recent action.
Sign-up for UPDATE: Broker does a 180 on Glaxo; shares surge investment picks
2015/2/13
By Russ Britt, MarketWatch Prana tumbles again after FDA puts hold on drug trial LOS ANGELES (MarketWatch)--Shares of drug maker GlaxoSmithKline jumped more than 4% Friday after brokerage UBS turned 180 degrees and upgraded the British multinational to "buy" from "sell." Shares of Glaxo (GSK) climbed $1.93 to $47.88 in recent action.
Sign-up for Broker does a 180 on Glaxo; shares surge investment picks
2015/2/12
By Russ Britt, MarketWatch Other attempts at cost control having minimal effect on system This is the last installment in a four-part series.
Sign-up for UPDATE: Health-care costs: It's time for patients to take control investment picks
2015/2/12
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for UPDATE: What to look for in CBS earnings investment picks
2015/2/11
By Russ Britt, MarketWatch This late-night host may be exceptionally hard to replace LOS ANGELES (MarketWatch)--It's been a tumultuous 12 months for late-night talk shows, with a number of hosts playing musical chairs, but Jon Stewart's departure from "The Daily Show With Jon Stewart" could have a broader impact than most of the other recent changes.
Sign-up for UPDATE: Jon Stewart's brand building not seen since Carson investment picks
2015/2/11
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for UPDATE: What to look for in CBS earnings investment picks
2015/2/10
By Russ Britt, MarketWatch Broadcaster aims to outpace potential reunion partner Viacom With the prospect of a reunion with Viacom Inc. on the horizon, the Street will be watching to see whether CBS Corp.
Sign-up for UPDATE: What to look for in CBS earnings investment picks
2015/2/10
By Russ Britt, MarketWatch Shares spike more than 10%; analysts cautiously optimistic LOS ANGELES (MarketWatch) -- A massive growth in enrollment, thanks largely to the expansion of Medicaid programs under Obamacare, boosted the earnings of insurer Molina Healthcare well past analyst estimates and sent the company's stock to an all-time high Tuesday.
Sign-up for Obamacare gives a lift to insurer Molina's results investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Amazon investors roll the dice on earnings to Obamacare gives a lift to insurer Molina's results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent